Concord Biotech Ltd IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow

Concord Biotech



+85.80 (5.94%)


Offer Price

₹ 1,550.52 Cr

Issue Size

₹ 14,820

Min Investment


Times Subscribed


Lot size

Time Line

  • 04
    Aug 2023
  • 08
    Aug 2023
  • 11
    Aug 2023
    Finalisation of Basis of Allotment
  • 14
    Aug 2023
    Initiation of Refunds
  • 17
    Aug 2023
    Transfer of Shares to Demat Account
  • 18
    Aug 2023
    Listing Date

Shares Offered

Number of Times Subscribed

Objects of the Offer

  • Continue to increase our API market share and further develop its portfolio of complex and niche APIs with high growth potential.

  • Increase the presence of its existing formulations and expand into new formulations.

  • Improve cost management and operational efficiencies.

  • Grow its CDMO business.

Products & Services

  • Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology.


  • Established presence across the complex fermentation value chain;

  • Global leadership in immunosuppressant APIs along with a wide spectrum of complex fermentation-based APIs across multiple therapeutic areas;

  • Scaled manufacturing facilities with a consistent regulatory compliance track record and supported by strong R&D capabilities;

  • Diversified global customer base with long-standing relationships with key customers;

  • Experienced Promoters, management team supported by marquee investors;


  • Any delay, interruption or reduction in the supply of its raw materials or the transportation of the company raw materials or products may adversely impact the pricing and supply of its products and have an adverse effect on its business.

  • Any manufacturing or quality control issues may damage its reputation, subject it to regulatory action, and expose the company to litigation or other liabilities, which could adversely affect its business, financial condition and results of operations.

  • A slowdown or shutdown in its manufacturing or research and development operations, all located in Gujarat, India, could adversely affect the company business, financial condition and results of operations.

  • The company depends on a limited number of key customers for a substantial portion of its revenues. Any significant reduction in demand for the company products from such customers may adversely affect its business and results of operations.

  • If the company is unable to obtain trademarks and patents for its products or protect such proprietary information, or inadvertently infringe on the patents of others, its business may be adversely affected.

Company Promoters

Promoters Holding

Issue For IPO
Pre Holding


Post Holding


Top Promoters Holding


All values in Cr

Mar-2022 Mar-2023 Mar-2023 3-Yr trend
Revenue 712.93 (15.70%) 853.17 (19.70%) 20.06 (-)
Gross Profit 712.93 (15.70%) 853.17 (19.70%) 20.06 (-)
Net Income 712.93 (15.70%) 853.17 (19.70%) 20.06 (-)
Assets 712.93 (15.70%) 853.17 (19.70%) 20.06 (-)
Liabilities 712.93 (15.70%) 853.17 (19.70%) 20.06 (-)


Company Name Revenue (Cr) Net Profit (Cr) Assets (Cr) Liabilities (Cr) ROE EPS BVPS Current Ratio Debt to Assets
Concord Biotech Ltd 853.17 240.09 1,323.85 33.85 20.06 22.95 123.31 3.08 0.02
Divi`s Laboratories Ltd 7,767.51 1,823.38 14,438.77 14,438.77 14.28 68.69 480.96 12.62 0.00
Suven Pharmaceuticals Ltd 1,340.33 411.29 1,965.74 1,965.74 23.70 16.16 68.16 20.92 0.00
Laurus Labs Ltd 6,040.55 790.11 7,660.40 7,660.40 19.56 14.64 75.16 10.31 0.49
Shilpa Medicare Ltd 1,050.11 -32.48 2,902.38 2,902.38 -1.82 -3.74 204.41 -1.11 0.45

Book Running Managers

  • Kotak Mahindra Capital Company Ltd
  • Citigroup Global Markets India Pvt Ltd
  • Jeffries India Pvt Ltd

Registrar & Transfer Agent

Link Intime India Pvt Ltd

C-101 247 Park,
L B S Marg,
Vikhroli West - Mumbai-400083
Phone : 91-22-49186000 Fax: 91-22-49186060

Company Contact Information

1482-86 Trasad Road,
Ahmedabad - 382225
Phone : 91-079-68138700 Email :

Offer Related Information

Initial public offer of 20,925,652* equity shares of face value of Re. 1 each ("Equity Shares") of Concord Biotech Limited ("Company") for cash at a price of Rs. 741 per equity share (including a premium of Rs. 740 per equity share) ("Offer Price") aggregating to Rs. 1550.52*^ crores (the "Offer") through an offer for sale of 20,925,652* equity shares aggregating to Rs. 1550.52*^ crores by Helix Investment Holdings Pte. Limited (the "Selling Shareholder") and such equity shares offered by the... More


  • No Data Found.

Take your research to the next level.
Login now to unlock Exclusive Features!

Take your research to the next level.
Login now to unlock Exclusive Features!

Download Our App On: